| |
Immune checkpoint inhibitors offer significant survival benefit, yet many patients do not respond to these treatments. Dosing optimization offers hope. Learn how to maximize therapeutic efficacy and minimize toxicity of ICIs in our guide.
|
|
Today’s Big NewsOct 3, 2024 |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now!
|
|
| By Nick Paul Taylor Septerna is about to find out how a biotech without “any meaningful clinical data” fares in the late 2024 IPO market. The G protein-coupled receptor specialist is asking investors to fund development of its lead hypoparathyroidism candidate through phase 2 before it shares initial data in humans. |
|
|
|
By James Waldron European VC firm Kurma Partners has unveiled its latest biotech fund, with 140 million euros ($154 million) raised so far and three biotech beneficiaries already named. |
By Darren Incorvaia Antibody aficionado GigaGen, a subsidiary of Spanish biopharma Grifols, is ramping up its tech to tackle botulinum neurotoxins to the tune of up to $135 million over six years. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
|
This white paper delves into key challenges in ADC development and explores new drug product capabilities in cytotoxic drug development and manufacturing, accelerating timelines to IND filing and beyond.
|
|
By James Waldron Pentixapharm has brought in almost 20 million euros ($22 million) from an IPO, with the German biotech earmarking the proceeds to push ahead with the clinical development of its two lead radiopharmaceuticals. |
By James Waldron A week after signing up to collaborate on a robotic cell therapy manufacturing system, Legend has unveiled plans for a new R&D site in Philadelphia. |
By Noah Tong CMS is looking to increase feedback from drug manufacturers and foster better communication with pharmacies as stakeholders prep for the next round of drug price negotiations. |
By Fraiser Kansteiner WuXi AppTec has put its cell and gene therapy manufacturing arm, WuXi Advanced Therapies, on the market, The Financial Times reported Thursday. At the same time, WuXi Biologics is working with advisors to gauge interest in some of its European production facilities, the news outlet added, citing sources. |
By Conor Hale The agency labeled the recall effort as Class I, its most serious, and said it received reports of nine injuries and one death. |
Fierce podcastsDon’t miss an episode |
| | In this week's "The Top Line," Fierce journalists discuss key issues from promising but debated lung cancer data at recent conferences. |
|
|---|
|
|
|
Optimize Bioprocessing with Scalable Solutions – Achieve Higher Yields, Greater Purity, and Faster Time-to-market.
|
|
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
| WhitepaperUnique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
| WhitepaperWhen the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
| WhitepaperPower non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
| Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
